The results of bioinformatics analysis, molecular docking, flow cytometry and quantitative PCR suggest that RHEBL1 and RNPC3 may be potential targets for Polyphyllin VI and Protodioscin in the treatment of non-small cell lung cancer. This evidence concerns the gene RHEBL1 and non-small cell lung carcinoma.